Ratings Redx Pharma Plc

Equities

Market Closed - Deutsche Boerse AG Other stock markets 06:59:02 30/04/2024 pm IST			5-day change	1st Jan Change
0.167 ^EUR	+67.00%		-.--%	-30.42%

16/05	Redx Pharma plc Appoints Claire Catherinet as Director	CI
15/05	Redx Pharma plc Announces the Termination of Dr Joseph Anderson as Director	CI

On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
The company's enterprise value to sales, at 4.81 times its current sales, is high.
For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
The group usually releases earnings worse than estimated.

	1st Jan change	Capi.	ESG Refinitiv
REDX PHARMA PLC	-30.42%	70.6M	-
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B	B+
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B	B+
BIONTECH SE	-4.68%	24.28B	B+
ARGENX SE	-0.82%	21.96B	B
GENMAB A/S	-10.12%	18.16B	A-
WUXI APPTEC CO., LTD.	-42.12%	16.37B	A-
BEIGENE, LTD.	-17.47%	15.56B	B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B	C+
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B	C+

Investor Rating

Trading Rating

ESG Refinitiv

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality